Senses Disorder TRIZ Cases

Pyridazinone-amide derivatives selectively inhibit IRAK-4 and IRAK-1 to treat inflammatory diseases without impairing immune defenses against infections.

Isotopically modified polyunsaturated fatty acids mitigate cytotoxic aldehyde accumulation by reducing oxidation through kinetic isotope effect.

Glucose-modified micelles overcome blood-brain barrier limitations to deliver siRNA into brain tissue while maintaining stability above the LCST.

High molecular weight polyethylene glycol suspends therapeutic agents in pharmaceutical formulations.

An implantable pump infuses artificial cerebrospinal fluid to increase intracranial pressure and enhance fluid turnover.

Solvent system adjustments resolve crystal structure definition gaps, delivering stable polymorphs with optimized solubility and bioavailability.

A bicistronic genetic construct delivers anti-VEGF and anti-fibrotic proteins via a recombinant AAV vector to treat retinal disorders.

Intranasal therapeutic cell delivery utilizes the olfactory neural pathway to transport cells directly to the central nervous system.

Polyamide compounds penetrate cellular membranes to selectively bind wild-type mitochondrial DNA, shifting heteroplasmy ratios to treat genetic diseases.

Monoclonal antibodies bind beta-amyloid proteins to reduce plaque load, addressing inadequate treatment efficacy and side effects.

Rabbit monoclonal antibodies neutralize tumor necrosis factor-alpha activity, reducing inflammation and tissue damage in rheumatoid arthritis.

Carbazole sulfonamide derivatives modulate cryptochrome proteins to stabilize Cry1 and Cry2, addressing glycemic control limitations in diabetes therapy.

A bicyclic compound lowers intraocular pressure via selective FP receptor agonism, avoiding IP and EP2/EP4 activation that causes ocular side effects.

A spiro compound acts as a GPR40 agonist to promote endogenous insulin secretion.

Substituting proline and isoleucine in NAP peptides reduces beta-sheet formation while maintaining neuroprotective activity against tau aggregation.

Imidazole urea derivatives modulate the N-formyl peptide receptor 2, addressing side effects like elevated intraocular pressure and delayed wound healing.

Segmented biodegradable polymer implants release antihypertensive agents over months, resolving low patient compliance from daily eye drops.

Alkylphosphocholine coatings on intraocular lenses prevent secondary cataract formation by inhibiting lens epithelial cell migration and adhesion.

Form A and Form B hydrates durably activate TMEM16A channels to resolve transient modulation limits in respiratory disease treatments.

Segmented purine structures inhibit PI3Kδ to resolve immune suppression trade-offs in inflammatory and cancer treatments.

A nutrient mixture containing vitamins, carotenoids, and plant extracts protects retinal pigment epithelium and corneal cells.

Engineered cysteine residues in the CH1 domain create free thiol groups for stable cytotoxic agent attachment, reducing toxicity to normal cells.

RNAi oligonucleotides targeting TSC2 reduce protein synthesis to improve photoreceptor survival and visual function.

P268 polysaccharide reduces IL-8 secretion and subconjunctival edema to address ineffective conventional treatments for dry eye syndrome.

Nutlin-3a blocks Hdm2-mediated p53 degradation to prevent proliferative vitreoretinopathy recurrence and reduce surgical burden.

Topically administered peptides activate the glucagon-like peptide-1 receptor to provide neuroprotection in the retina.

Reconstituted high-density lipoprotein infusion restores endothelial function in diabetic patients.

Combination therapy merges anti-EGFR antibodies with VEGFR inhibitors to resolve incomplete tumor regression caused by single-agent resistance.

Alkylated glycosaminoglycan ethers resolve the anticoagulant trade-off by blocking inflammatory pathways without bleeding risks.

A bispecific fusion protein crosslinks CTLA-4 to the T cell receptor via a tri-molecular complex.

Retinol-like eye compositions stimulate corneal epithelial cells to produce and release mucin, addressing insufficient secretion in dry eye syndrome.

Knead omega-3 fatty acid paste with amines at 130°C to prevent foaming and reduce energy consumption during evaporation.

A gene vector incorporates microRNA target sequences to enable precise transgene expression control.

Formula I pyridazino-pyridinone compounds inhibit p38 kinase to reduce pro-inflammatory cytokine production in rheumatoid arthritis.

A pharmaceutical composition combines a self-assembling polypeptide with organic solvents to form a sustained-release hydrogel depot.

Intravitreal NO-PDE5 inhibitors improve choroidal circulation and provide neuroprotection against dry AMD progression.

Peptides with unnatural amino acids resist calpain cleavage while inhibiting CAPN5, addressing the unknown molecular cause of ADNIV.

A five-step enantioselective synthesis produces amino ceramide-like compounds with high purity using inexpensive reagents.

Specific albumin to sodium chloride weight ratios prevent denaturation and activity loss during storage.

Apelin antibodies bind the APJ receptor to block angiogenic signaling, resolving limited treatment options for diabetic retinopathy.

Periodic administration of VEGF antagonists at eight-week intervals reduces treatment burden while maintaining disease control.

Combining Ascl1 with HDAC inhibitors boosts neurogenesis from Müller glia, resolving low reprogramming efficiency.